Shares of Gland Pharma experienced a significant rally on Monday, surging more than 16% during the trading session. This surge followed the company's robust financial performance for the quarter ended March 31, 2026 (Q4 FY26), which saw its net profit nearly double.
Q4 FY26 Performance Highlights
For the fourth quarter of the fiscal year 2026, Gland Pharma reported a net profit of Rs 186.5 crore, marking an impressive 96.6% year-on-year (YoY) jump. Revenue from operations also saw a healthy increase, growing by 22% YoY to reach Rs 1,743 crore. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stood at Rs 513 crore, up 48% YoY, with margins improving to 29.4% for the quarter. Additionally, Gland Pharma announced a final dividend of Rs 20 per share.
A key driver for this growth was the Contract Development and Manufacturing Organization (CDMO) segment, which contributed 25% of total revenues and expanded by 65% on a yearly basis. The company also benefited from a favorable product mix and strategic cost-efficiency initiatives, leading to an adjusted EBITDA margin of 38% in its base business.
Stock Performance and Analyst Outlook
The strong Q4 results propelled Gland Pharma's stock to a 52-week high of Rs 2,170, pushing its total market capitalization beyond Rs 35,000 crore. Over the past three years, the company's shares have gained 133%, with nearly 50% growth recorded in the last year alone.
Following the earnings report, several brokerage firms reiterated their positive outlook on Gland Pharma. Elara Capital noted that the Q4 results surpassed their expectations, particularly in EBITDA and PAT, and maintained a 'buy' rating with a target price of Rs 2,306. They highlighted new complex product launches and new contracts in regulated markets as key contributors.
Motilal Oswal Financial Services also echoed a 'buy' recommendation, setting a target price of Rs 2,300. They attributed the better-than-expected performance to an all-time high revenue in core markets driven by new product launches, and healthy scale-up in inactivated vaccine and sterile ophthalmic gel in the Europe segment. Motilal Oswal anticipates a 19% earnings CAGR over FY26-28, supported by a robust pipeline of complex injectable products.
Management guidance indicates a 12-13% constant-currency top-line growth for FY27, aligning with analyst expectations for continued positive momentum.